Cancer risks of people with inherited PALB2 mutations
Full article: https://doi.org/10.1200/JCO.19.01907
In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- I have an inherited PALB2 mutation. What is my risk of cancer?
- Given my inherited PALB2 mutation, what preventive options should I consider?
- I have been diagnosed with cancer; does my mutation status alter treatment recommendations?
- I have a family history of cancer but I have not had genetic testing; should I consider genetic testing?
- How do I contact a genetic counselor?
Open Clinical Trials
The following are risk-management studies enrolling people with inherited mutations. Check study listings or contact the study team to see if you are eligible.
- NCT02665195: Prospective Registry Of MultiPlex Testing (PROMPT). PROMPT is an online research registry for people who have had genetic panel testing. The goal of the PROMPT Registry is to follow people with mutations or variants in genes on these panels, so that patients, physicians and researchers can more clearly understand these lesser-known risks. This study is open to people with an inherited mutation or VUS in a number of different genes, including: ATM, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D and others.
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in this high-risk population.
- NCT03805919: Men at High Genetic Risk for Prostate Cancer. This is a prostate cancer screening study using MRI in high risk men. This study is open to men with ATM, BRCA1, BRCA2, BRIP1, CHEK2, HOXB13, Lynch syndrome, NBN, RAD51D, TP53 and other inherited mutations.
- NCT05129605: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS). This study will look at how well prostate MRI works as a screening tool for men at high risk for prostate cancer. This study is open to men with inherited mutations in ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53 and other genes.
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a test to detect ovarian cancer. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. The study is enrolling people with BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, Lynch syndrome and other mutations.
- NCT05287451: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study will look at outcomes in women with BRCA1, BRCA2, BRIP1, RAD51C and RAD51D who remove their fallopian tubes first, followed by removal of their ovaries compared to women who undergo standard-of-care removal of their ovaries and fallopian tubes at the same time.
Additional risk-management clinical trials for people with inherited mutations may be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.